Compare · CSTL vs ILMN
CSTL vs ILMN
Side-by-side comparison of Castle Biosciences Inc. (CSTL) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CSTL and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $24.35B, about 38.8x CSTL ($627.8M).
- Over the past year, CSTL is up 7.3% and ILMN is up 78.2% - ILMN leads by 70.9 points.
- CSTL has been more active in the news (18 items in the past 4 weeks vs 12 for ILMN).
- ILMN has more recent analyst coverage (25 ratings vs 5 for CSTL).
- Company
- Castle Biosciences Inc.
- Illumina Inc.
- Price
- $20.68-1.43%
- $160.92-3.10%
- Market cap
- $627.8M
- $24.35B
- 1M return
- +14.13%
- +11.01%
- 1Y return
- +7.32%
- +78.21%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2000
- News (4w)
- 18
- 12
- Recent ratings
- 5
- 25
Castle Biosciences Inc.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest CSTL
- Pres. & Chief Exec. Officer Maetzold Derek J exercised 6,214 shares at a strike of $2.39 and sold $205,149 worth of shares (9,836 units at $20.86) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Castle Biosciences Inc.
- SEC Form 4 filed by Director Olson Tiffany
- SEC Form 4 filed by Director Goldberg Ellen
- SEC Form 4 filed by Director Harrison Miles
- SEC Form 4 filed by Director Cotton Rodney
- SEC Form 4 filed by Director Caple Kim
- SEC Form 4 filed by Director Bradbury Daniel
- SEC Form 4 filed by Director Cole G Bradley
- Castle Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest ILMN
- Illumina upgraded by Analyst with a new price target
- SVP, Chief People Officer Leckman Patricia sold $127,305 worth of shares (783 units at $162.59), decreasing direct ownership by 4% to 21,259 units (SEC Form 4)
- Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
- SVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research